» Articles » PMID: 22320795

Three-dimensional Lung Tumor Segmentation from X-ray Computed Tomography Using Sparse Field Active Models

Overview
Journal Med Phys
Specialty Biophysics
Date 2012 Feb 11
PMID 22320795
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Manual segmentation of lung tumors is observer dependent and time-consuming but an important component of radiology and radiation oncology workflow. The objective of this study was to generate an automated lung tumor measurement tool for segmentation of pulmonary metastatic tumors from x-ray computed tomography (CT) images to improve reproducibility and decrease the time required to segment tumor boundaries.

Methods: The authors developed an automated lung tumor segmentation algorithm for volumetric image analysis of chest CT images using shape constrained Otsu multithresholding (SCOMT) and sparse field active surface (SFAS) algorithms. The observer was required to select the tumor center and the SCOMT algorithm subsequently created an initial surface that was deformed using level set SFAS to minimize the total energy consisting of mean separation, edge, partial volume, rolling, distribution, background, shape, volume, smoothness, and curvature energies.

Results: The proposed segmentation algorithm was compared to manual segmentation whereby 21 tumors were evaluated using one-dimensional (1D) response evaluation criteria in solid tumors (RECIST), two-dimensional (2D) World Health Organization (WHO), and 3D volume measurements. Linear regression goodness-of-fit measures (r(2) = 0.63, p < 0.0001; r(2) = 0.87, p < 0.0001; and r(2) = 0.96, p < 0.0001), and Pearson correlation coefficients (r = 0.79, p < 0.0001; r = 0.93, p < 0.0001; and r = 0.98, p < 0.0001) for 1D, 2D, and 3D measurements, respectively, showed significant correlations between manual and algorithm results. Intra-observer intraclass correlation coefficients (ICC) demonstrated high reproducibility for algorithm (0.989-0.995, 0.996-0.997, and 0.999-0.999) and manual measurements (0.975-0.993, 0.985-0.993, and 0.980-0.992) for 1D, 2D, and 3D measurements, respectively. The intra-observer coefficient of variation (CV%) was low for algorithm (3.09%-4.67%, 4.85%-5.84%, and 5.65%-5.88%) and manual observers (4.20%-6.61%, 8.14%-9.57%, and 14.57%-21.61%) for 1D, 2D, and 3D measurements, respectively.

Conclusions: The authors developed an automated segmentation algorithm requiring only that the operator select the tumor to measure pulmonary metastatic tumors in 1D, 2D, and 3D. Algorithm and manual measurements were significantly correlated. Since the algorithm segmentation involves selection of a single seed point, it resulted in reduced intra-observer variability and decreased time, for making the measurements.

Citing Articles

Radiology and Enterprise Medical Imaging Extensions (REMIX).

Erdal B, Prevedello L, Qian S, Demirer M, Little K, Ryu J J Digit Imaging. 2017; 31(1):91-106.

PMID: 28840365 PMC: 5788816. DOI: 10.1007/s10278-017-0010-6.


Automatic lung tumor segmentation with leaks removal in follow-up CT studies.

Vivanti R, Joskowicz L, Karaaslan O, Sosna J Int J Comput Assist Radiol Surg. 2015; 10(9):1505-14.

PMID: 25605297 DOI: 10.1007/s11548-015-1150-0.


2D-3D radiograph to cone-beam computed tomography (CBCT) registration for C-arm image-guided robotic surgery.

Liu W, Otake Y, Azizian M, Wagner O, Sorger J, Armand M Int J Comput Assist Radiol Surg. 2014; 10(8):1239-52.

PMID: 25503592 PMC: 4476946. DOI: 10.1007/s11548-014-1132-7.


Consistency and efficiency of CT analysis of metastatic disease: semiautomated lesion management application within a PACS.

Folio L, Sandouk A, Huang J, Solomon J, Apolo A AJR Am J Roentgenol. 2013; 201(3):618-25.

PMID: 23971455 PMC: 6771287. DOI: 10.2214/AJR.12.10136.


Harnessing technology to improve clinical trials: study of real-time informatics to collect data, toxicities, image response assessments, and patient-reported outcomes in a phase II clinical trial.

Pietanza M, Basch E, Lash A, Schwartz L, Ginsberg M, Zhao B J Clin Oncol. 2013; 31(16):2004-9.

PMID: 23630218 PMC: 4878068. DOI: 10.1200/JCO.2012.45.8117.